BPC-157 vs TB-500
Side-by-side literature comparison of two of the most-cited healing-model tool peptides in the published preclinical and in-vitro research corpus.
Side-by-Side Attributes
Objective data pulled from the published peptide literature. For research context only — not efficacy or performance claims.
| Attribute | BPC-157 | TB-500 |
|---|---|---|
| Class | Pentadecapeptide (15-mer) | Thymosin-Beta-4 fragment (typically 17-mer or 4-mer LKKTETQ) |
| Sequence | Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val | Ac-SDKPDMAEIEKFDKSKLKKTETQEKNPLPSKETIEQEKQAGES-OH (TB-4) / LKKTETQ fragment (TB-500) |
| Molecular Weight | 1419.54 Da | ~4963 Da (TB-4 full-length); ~889 Da (LKKTETQ fragment) |
| Origin | Fragment of gastric juice BPC (Body Protective Compound) | Fragment of Thymosin Beta-4, an abundant intracellular protein |
| First described | Zagreb group (Sikiric et al.), 1991 | Goldstein lab, ~1981 (TB-4); TB-500 fragment emerged in the 1990s literature |
| Synthesis complexity | Straightforward Fmoc SPPS (short linear) | Straightforward Fmoc SPPS (short linear fragment); full TB-4 more complex |
| Primary literature receptor/target | Nitric oxide (NO) pathway signalling; not receptor-defined | G-actin sequestration (binds monomeric actin at ~1:1 stoichiometry) |
| In-vitro solubility | Water-soluble; commonly reconstituted with bacteriostatic water | Water-soluble; commonly reconstituted with bacteriostatic water |
| Stability | Reported stable in gastric fluid — an unusual literature note for a peptide | Reported stability comparable to other short linear peptides |
| Endotoxin release spec (BioInfinity) | < 0.5 EU/mg by LAL | < 0.5 EU/mg by LAL |
| Third-party COA lab (BioInfinity) | Verum Analytics, Switzerland | Verum Analytics, Switzerland |
Literature Context
BPC-157 and TB-500 are frequently cited together in the published wound-healing model literature — often in co-treatment in-vitro protocols. Despite the surface similarity in research context, the two compounds engage fundamentally different molecular pathways: BPC-157 is investigated in the literature via nitric-oxide (NO) signalling and angiogenesis-related pathways, while TB-500 (and its parent protein TB-4) is studied as an actin-sequestering peptide that modulates cytoskeletal dynamics.
From a synthesis standpoint, both are short linear peptides that are readily produced by Fmoc solid-phase peptide synthesis (SPPS) and purified to ≥99% by preparative reverse-phase HPLC. TB-500 as commonly sold refers to a shorter synthetic fragment (typically the 17-mer or the 4-mer LKKTETQ motif) rather than the full 43-residue TB-4 protein, which makes it comparable in synthesis complexity to BPC-157.
Both peptides appear in the fibroblast, endothelial migration, angiogenesis, and cytoprotection-model in-vitro literature. Neither is FDA-approved for any therapeutic indication; both are supplied by BioInfinity strictly for laboratory research.
Research Contexts in the Literature
Overlapping
- Fibroblast proliferation assays
- Endothelial cell migration models
- Angiogenesis / tube-formation assays
- Wound-scratch closure in-vitro protocols
- Nitric-oxide signalling context (BPC-157 direct; TB-500 downstream)
BPC-157 only
- Gut epithelial barrier / TEER integrity studies
- Dopaminergic signalling preclinical models
- Growth-hormone / IGF-1 axis expression studies
- Gastric fluid stability literature
TB-500 only
- G-actin sequestration stoichiometry assays
- Cardiomyocyte proliferation preclinical models
- Corneal epithelial repair models
- Hair-follicle stem-cell literature
All products supplied by BioInfinity are for in-vitro laboratory research use only. Not FDA-approved. Not intended for human or veterinary use. This page is a literature summary — not medical, dosing, or usage guidance.